ArticleEuropean journal of medical research2026
Deciphering stromal cell interactions in osteosarcoma highlights CDKN2A and MMP14 as novel diagnostic and therapeutic biomarkers.
Article in European journal of medical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundOsteosarcoma (OS) progression is critically influenced by the stromal microenvironment, yet we face a lack of reliable biomarkers. This study integrated single-cell and transcriptomic analyses to decipher stromal cell networks and identify novel diagnostic markers and therapeutic targets for OS.
methodsUsing scRNA-Seq data and transcriptomic datasets obtained from the Gene Expression Omnibus (GEO), clustering analysis and communication analysis were performed with Seurat and CellChat packages, respectively. High-dimensional WGCNA (hdWGCNA) was applied to stromal cells to identify key gene modules. Hub genes from these modules were intersected with differentially expressed genes (DEGs) from DESeq2 analysis to pinpoint potential biomarkers. Their regulatory networks were predicted using the hTFtarget and ENCORI databases. Potential targeted drugs were screened via the DSigDB database and validated by molecular docking. Finally, functional assays were conducted using OS cell lines.
resultsSingle-cell transcriptomics analysis identified seven major cell subpopulations (macrophages, stromal cells, T cells, plasma cells, endothelial cells, plasmacytoid dendritic cells, and mast cells). Cell communication analysis showed that stromal cells and macrophages can interact via CD99-CD99. hdWGCNA analysis clustered 19 gene modules in stromal cells, among which modules M14, M15, and M17 were closely associated with OS and enriched in pathways, such as ossification, extracellular matrix organization, and skeletal system development. Two potential biomarkers (CDKN2A and MMP14) were screened. Transcription factor (TF) and miRNA regulatory network predictions indicated that both the two potential biomarkers were situated in a complex post-transcriptional regulatory network. Drug prediction and molecular docking results revealed that MMP14 can stably bind to resveratrol. The proliferation, invasion, and migration capabilities of MMP14-silenced OS cell lines were significantly downregulated.
conclusionThis study identified CDKN2A and MMP14 as potential OS biomarkers and elucidated their role within the stromal cell network, suggesting resveratrol as a candidate therapeutic molecule targeting MMP14. The present discoveries provided new insights for understanding the progression mechanisms and developing precise diagnosis and treatment strategies for OS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.